Theratope vaccine

Theratope® vaccine

Oncology A synthetic vaccine designed to stimulate the immune system to combat metastatic breast, colorectal and other CAs. See Therapeutic vaccine.
References in periodicals archive ?
Biomira's lead product, THERATOPE vaccine, is currently in a Phase III trial for women with metastatic breast cancer.
The company's lead product candidate, THERATOPE vaccine, also has broad potential for immunotherapy of cancers.
Edmonton, Canada; 403-490-2818) announced that the company was issued a patent from the United States Patent and Trademark Office on August 25, 1998, for technology used in its THERATOPE vaccine.
This application relates to the THERATOPE vaccine manufacturing process.
In Phase II clinical trials, patients with metastatic breast cancer appeared to show a survival benefit associated with the use of THERATOPE vaccine.